Peptide LibraryARA 290 (Cibinetide) dosage in published studies and labels
These are the doses used for ARA 290 (Cibinetide) in FDA labelling and published clinical studies, reported as each source states them, one row per regimen. They describe what was studied or approved for a specific population. They are not a recommendation, and none of them is a dose for any individual.
Research and educational reference only. This is not medical advice, and no figure on this page is a dosing recommendation.
Last checked against primary sources:
Studied regimens and sources
ARA 290 (cibinetide) has no approved dosage. Human dosing comes from phase 2 trials of daily injections under the skin for 28 days. In 64 people with sarcoidosis-related small nerve fiber loss, 1, 4 or 8 mg a day were compared with placebo, and only 4 mg significantly increased corneal nerve fiber area; a type 2 diabetes study used 4 mg a day.
| Human dosing established | Yes |
|---|---|
| Studied dose range | 1–8 mg once daily in phase 2 trials |
| Route | Subcutaneous |
| Frequency | Once daily |
| Duration studied | 28 days in the published trials |
| Evidence level | Clinical Trial Evidence |
| Last reviewed | 2026-11-07 |
Research-reported dosing
Doses as studied, one row per regimen. Different trials used different regimens; they are listed separately rather than averaged.
| Study / context | Population | Dose | Route | Frequency | Duration | Outcome studied | Source |
|---|---|---|---|---|---|---|---|
| Phase 2b, sarcoidosis-associated small nerve fiber loss (NCT02039687)Clinical trial · Randomized, placebo-controlled phase 2b trial | Adults with sarcoidosis, small nerve fiber loss and neuropathic pain (n=64) | 1, 4 or 8 mg | Subcutaneous | Once daily | 28 days | Corneal nerve fiber area increased significantly with 4 mg only; pain improved in all groups | Cibinetide Improves Corneal Nerve Fiber Abundance in Patients With Sarcoidosis-Associated Small Nerve Fiber Loss and Neuropathic Pain. Invest Ophthalmol Vis Sci. 2017. |
| Phase 2, type 2 diabetes with painful neuropathy (2015)Clinical trial · Randomized, placebo-controlled phase 2 trial | Adults with type 2 diabetes and painful neuropathy | 4 mg | Subcutaneous (self-administered) | Once daily | 28 days, followed for another month | Improved HbA1c, lipids and neuropathic symptom scores versus placebo | ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes. Mol Med. 2015. |
Where sources disagree
- The trials are small, phase 2 and 28 days long. Surrogate endpoints such as corneal nerve fiber area were the primary measures, and no phase 3 trial has been published.
- ARA 290 is engineered from erythropoietin but is designed not to stimulate red blood cell production; erythropoietin doses do not apply to it.